Related Experiment Video
Updated: Jul 4, 2026
04:41
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
S Minden1, D Hoaglin, S Jureidini
1Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. sarahminden@gmail.com
Multiple Sclerosis (Houndmills, Basingstoke, England)
|June 21, 2008
Summary
Many multiple sclerosis patients do not use disease-modifying agents (DMAs) as recommended, despite their benefits in slowing progression. Understanding reasons for non-use and discontinuation is key to improving treatment adherence for better patient outcomes.
Area of Science:
- Neurology
- Public Health
Background:
- Experts recommend early and continuous use of disease-modifying agents (DMAs) for multiple sclerosis (MS) to prevent axonal damage and disability.
- However, many MS patients either do not initiate or prematurely discontinue DMA treatment.
Purpose of the Study:
- To determine the rates, predictors, and reasons for DMA use, non-use, and discontinuation in a population-based sample of MS patients.
- To identify factors influencing treatment adherence and persistence.
Main Methods:
- A population-based sample of 2156 individuals with MS was surveyed regarding their use of and experiences with DMAs.
- Chi-squared tests and logistic regression were employed to analyze usage patterns and identify predictors of DMA use.
Main Results:
- Half of the participants were current DMA users, while 12.2% had previously used DMAs but discontinued.
- Reasons for non-use and discontinuation often contradicted expert recommendations.
- Regular neurologist care was a significant factor in initiating and maintaining DMA therapy.
Conclusions:
- There is a need to disseminate expert recommendations and management strategies for DMAs to non-neurologic healthcare providers, patients, and their families.
- Improved communication and education may encourage more appropriate candidates to start and continue DMA treatment, ultimately improving MS management.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...